What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (002399.SZ) StockRank?

MoatMap's StockRank for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) is 67/100, with a Buy signal. This is a composite score combining Quality (54), Value (52), and Momentum (48) factor ranks across MoatMap's 19,000+ stock universe.

Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. have an economic moat?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

002399.SZ

BUYREMOVE

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. · Healthcare · China · $2.2B · Avg Vol: $6M/d

StockRank

P/E (TTM)

35.2x

ROE

3.0%

D/E

0.3x

Dividend %

1.6%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Shenzhen Hepalink is a heparin sodium API manufacturer and CDMO. While it has CDMO exposure, its core heparin business has suffered from severe pricing pressure, regulatory scrutiny, and supply chain volatility, failing our quality compounder filter.

COMPANY DESCRIPTION

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a leading global pharmaceutical company specializing in the development and manufacture of heparin-related products, including heparin sodium API and enoxaparin sodium injections. As one of the world's largest suppliers of heparin, the company benefits from a vertically integrated global supply chain that ensures strict quality control and traceability. Its strong regulatory approvals from the FDA and EMA enable it to command a significant share of the European and US markets.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	1.1B	805M	780M	810M	-8.5%
EPS	0.07	-0.08	0.07	0.04	-21.7%
Shares	1.5B	1.5B	1.5B	1.5B	0.0%
Debt	955M	822M	524M	439M	-22.8%
Equity	1.8B	1.8B	1.8B	1.8B	-0.8%
Op CF	-112M	59M	324M	253M	107.4%
Inv CF	37M	181M	-61M	-129M	—
Fin CF	49M	-179M	-316M	-162M	—

PRICE (1M)-17.3%

SMA 50SMA 200

$1.34

RSI (14)

29.4

52W High

$2.12

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

3.7%53.2

ROE

3.0%51.2

GP/Assets

10.7%27.2

Op. Margin

14.3%73.8

FCF/Assets

7.7%80.3

Piotroski

—83.5

Int. Cover

6.6x58.2

D/E Ratio

0.27x45.7

Current Ratio

2.15x39.8

Value

P/E (TTM)

35.2x30.9

EV/EBITDA

14.3x29.4

P/FCF

77.8x81.4

P/B

1.1x76.3

P/S

2.5x61.5

Div Yield

1.6%41.4

Momentum

52W High %

63%46.1

RS 6M

-33%37.9

SMA 50/200

0.90x32.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—75.1

Q Growth

20%62.9

FUNDAMENTALS

Market Cap

$2.2B

P/E (Forward)

16.7x

Gross Margin

32.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002399.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
002399.SZ	Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(you)	$2.2B	67	BUY
603858.SS	Shandong Buchang Pharmaceuticals Co., Ltd.	$2.3B	66	BUY
301246.SZ	Hubei Hongyuan Pharmaceutical Technology Co., Ltd.	$1.9B	66	BUY
603707.SS	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.	$1.9B	65	BUY
300142.SZ	Walvax Biotechnology Co., Ltd.	$3.0B	67	BUY
000623.SZ	Jilin Aodong Pharmaceutical Group Co., Ltd.	$3.0B	69	BUY
603456.SS	Zhejiang Jiuzhou Pharmaceutical Co., Ltd	$1.7B	62	HOLD
002550.SZ	Changzhou Qianhong Biopharma CO.,LTD	$1.2B	66	BUY
002317.SZ	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	$3.0B	60	HOLD
002773.SZ	Chengdu Kanghong Pharmaceutical Group Co., Ltd	$2.9B	75	BUY

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.2%

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) — Stock Score Summary

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) has a MoatMap StockRank of 67/100 based on Quality (54/100), Value (52/100), and Momentum (48/100) factor scores. The current signal is BUY. Shenzhen Hepalink is a heparin sodium API manufacturer and CDMO. While it has CDMO exposure, its core heparin business has suffered from severe pricing pressure, regulatory scrutiny, and supply chain volatility, failing our quality compounder filter.

Key Financial Metrics

Price	$1.34
Market Cap	$2.2B
P/E (TTM)	35.23
P/E (Forward)	16.65
Price/Book	1.10
Return on Equity	3.0%
Return on Invested Capital	3.7%
Debt/Equity	26.68
Gross Margin	32.9%
Operating Margin	14.3%
Revenue Growth	-4.5%
Dividend Yield	1.6%
Free Cash Flow	$28M

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd.’s (002399.SZ) StockRank?: MoatMap’s StockRank for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) is 67/100, with a Buy signal. It is a composite of Quality (54), Value (52), and Momentum (48) factor ranks across MoatMap’s 19,000+ stock universe.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. have an economic moat?: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in?: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).